NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue TTM

0 3.5M 7M 10.5M Q4 '21: 178.1K Q1 '22: 140.4K Q2 '22: 158.8K Q3 '22: 150.7K Q4 '22: 171.2K Q1 '23: 252K Q2 '23: 681.6K Q3 '23: 1.3M Q4 '23: 2M Q1 '24: 2.8M Q2 '24: 3.7M Q3 '24: 3.9M Q4 '24: 3.5M Q1 '25: 5.7M Q2 '25: 5.8M Q3 '25: 6.6M Q4 '25: 9.1M Q1 '26: 8.7M Q2 '26: 9.2M Q3 '26: 9.5M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Gross Profit TTM

-2M 0 2M 4M 6M Q4 '21: -97.7K Q1 '22: -73.2K Q2 '22: -88.3K Q3 '22: -72.9K Q4 '22: -70.8K Q1 '23: -70K Q2 '23: -2.3K Q3 '23: 247.8K Q4 '23: 456.5K Q1 '24: 735.1K Q2 '24: 1.1M Q3 '24: 1.1M Q4 '24: 1.1M Q1 '25: 2.7M Q2 '25: 3.1M Q3 '25: 3.8M Q4 '25: 5.1M Q1 '26: 4.8M Q2 '26: 5M Q3 '26: 5.3M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Income TTM

-15M -10M -5M 0 5M 10M 15M Q4 '21: -10.2M Q1 '22: -10.9M Q2 '22: -11.5M Q3 '22: -11.3M Q4 '22: -10M Q1 '23: -9M Q2 '23: -9.4M Q3 '23: -10.2M Q4 '23: -12M Q1 '24: -13.6M Q2 '24: -13M Q3 '24: -12.2M Q4 '24: -11.9M Q1 '25: -6.8M Q2 '25: -6.6M Q3 '25: -5.7M Q4 '25: -4.2M Q1 '26: -7.6M Q2 '26: -7.4M Q3 '26: -7.9M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Net Income TTM

-15M -10M -5M 0 5M 10M 15M Q4 '21: -9.9M Q1 '22: -10.8M Q2 '22: -11.5M Q3 '22: -11.3M Q4 '22: -10M Q1 '23: -8.9M Q2 '23: -9.4M Q3 '23: -10.1M Q4 '23: -11.9M Q1 '24: -13.5M Q2 '24: -12.8M Q3 '24: -12.1M Q4 '24: -12.3M Q1 '25: -7.2M Q2 '25: -6.6M Q3 '25: -5.3M Q4 '25: -3.6M Q1 '26: -6.8M Q2 '26: -6.9M Q3 '26: -7.4M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Cost of Revenue TTM

0 1.5M 3M 4.5M Q4 '21: 275.9K Q1 '22: 213.6K Q2 '22: 247.1K Q3 '22: 223.6K Q4 '22: 242K Q1 '23: 322K Q2 '23: 683.9K Q3 '23: 1M Q4 '23: 1.5M Q1 '24: 2.1M Q2 '24: 2.6M Q3 '24: 2.8M Q4 '24: 2.4M Q1 '25: 3M Q2 '25: 2.6M Q3 '25: 2.9M Q4 '25: 4M Q1 '26: 3.9M Q2 '26: 4.2M Q3 '26: 4.2M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '21: -8.6M Q1 '22: -9.4M Q2 '22: -10.2M Q3 '22: -10.6M Q4 '22: -7.5M Q1 '23: -8.3M Q2 '23: -8.7M Q3 '23: -9M Q4 '23: -12.9M Q1 '24: -13.2M Q2 '24: -11.8M Q3 '24: -11.2M Q4 '24: -11M Q1 '25: -7M Q2 '25: -4.9M Q3 '25: -4M Q4 '25: -2.8M Q1 '26: -6.2M Q2 '26: -7.4M Q3 '26: -7.1M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '20: -3.5M Q2 '22: -10.4M Q3 '22: -10.8M Q4 '22: -7.8M Q1 '23: -8.6M Q2 '23: -9M Q3 '23: -9.4M Q4 '23: -13.3M Q1 '24: -13.6M Q2 '24: -12.1M Q3 '24: -11.4M Q4 '24: -11.1M Q1 '25: -7.1M Q2 '25: -5M Q3 '25: -4.1M Q4 '25: -2.9M Q1 '26: -6.3M Q2 '26: -7.6M Q3 '26: -7.2M Q4 '20 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '13: 5.1M Q3 '13: 4.5M Q4 '13: 4.5M Q2 '21: 11.2M Q3 '21: 12M Q1 '22: 15.4M Q2 '22: 16.2M Q3 '22: 16.2M Q1 '23: 16.2M Q2 '23: 16.4M Q3 '23: 17.6M Q1 '24: 24M Q2 '24: 25.9M Q3 '24: 27.4M Q1 '25: 30.9M Q2 '25: 5.2M Q3 '25: 8.1M Q1 '26: 50.3M Q2 '26: 8.5M Q3 '26: 8.7M Q3 '13 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q4 '21: -0.94 Q1 '22: -0.86 Q2 '22: -0.84 Q3 '22: -0.76 Q4 '22: -0.63 Q1 '23: -0.56 Q2 '23: -0.58 Q3 '23: -0.61 Q4 '23: -0.65 Q1 '24: -0.68 Q2 '24: -0.58 Q3 '24: -0.48 Q4 '24: -0.46 Q1 '25: -0.26 Q2 '25: -0.59 Q3 '25: -0.68 Q4 '25: -0.09 Q1 '26: -0.18 Q2 '26: -0.02 Q3 '26: -0.11 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.